MannKind Corp. Stock
MannKind Corp. Stock
There is an upward development for MannKind Corp. compared to yesterday, with an increase of €0.080 (1.620%).
With 24 Buy predictions and not a single Sell prediction MannKind Corp. is an absolute favorite of our community.
With a target price of 8 € there is a hugely positive potential of 57.98% for MannKind Corp. compared to the current price of 5.06 €.
So far the community has only identified positive things for MannKind Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of MannKind Corp. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | 1.620% | 3.707% | 11.689% | -19.157% | -22.331% | 10.568% | 106.189% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
MannKind (NASDAQ:MNKD) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $7.00 price target on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (NASDAQ:MNKD) had its price target lowered by analysts at Royal Bank Of Canada from $8.00 to $7.50. They now have an "outperform" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
MannKind (MNKD) Q2 Revenue Rises 6%
MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from
